Alzheimer’s Drugs Targeting Amyloid Don’t Help, Review Finds

Alzheimer’s drugs that target the buildup of the amyloid protein on the brain don’t meaningfully help patients, a major review found, raising questions about medicines developed by the likes of Eli Lilly & Co. and Eisai Co.

Despite successfully removing amyloid from the brain, the drugs don’t improve cognitive function or slow its decline, according to the review of drug trials on patients with mild symptoms due to Alzheimer’s disease. The study — called a Cochrane review and considered the gold-standard of research as it synthesizes evidence from multiple trials — looked at multiple drugs that target amyloid. ...